Analysis of the six-month treatment course of Eltrombopag/Eltrombopag

Eltrombopag/Eltrombopag, as an innovative oral biologic drug, is unique in that it is a low molecular weight, synthetic non-peptide thrombopoietin receptor agonist. This drug can precisely bind to the thrombopoietin receptor on platelets, megakaryocytes and their precursor cells. Its binding area is the transmembrane and juxtamembrane portion of the receptor, thus triggering a biological response similar to recombinant human thrombopoietin. It is worth mentioning that eltrombopag does not compete with the binding site of thrombopoietin on the receptor, showing a high degree of selectivity.

In multiple 6-week and 6-month clinical trials, Eltrombopag has demonstrated significant therapeutic effects. Eltrombopag was more effective than placebo in increasing platelet counts and reducing bleeding events, and was well tolerated by most patients. Longer non-comparative trial data (average duration reached 100 weeks) further corroborated these findings. It is worth mentioning that whether the patient has previously undergone splenectomy does not seem to affect the therapeutic effect of eltrombopag.

Eltrombopag is the first approved oral thrombopoietin receptor agonist. Its convenient administration gives it unique advantages in the treatment of difficult-to-treat chronic immune thrombocytopenia (ITP) and severe aplastic anemia (SAA). Since such conditions often require long-term treatment and management, and currently there is no radical cure, eltrombopag is often selected as the drug of choice for long-term treatment of patients with chronic ITP due to its good efficacy and tolerability.